Monte Rosa Therapeutics (GLUE) Operating Leases (2022 - 2026)

Monte Rosa Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $34.6 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 8.99% year-over-year to $34.6 million in Q1 2026; TTM through Mar 2026 was $34.6 million, a 8.99% decrease from a year earlier, with the FY2025 full-year figure at $34.8 million, down 10.79% from the prior year.
• Operating Leases slipped to $34.6 million in Q1 2026 per GLUE's latest filing, from $34.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $46.1 million in Q2 2022 and bottomed at $5.5 million in Q1 2022.
• The 5-year median for Operating Leases is $40.9 million (2024), against an average of $38.5 million.
• Across the five-year window, Operating Leases jumped 693.02% in 2023 and retreated 10.79% in 2025, its largest moves.
• Year by year, Operating Leases stood at $43.9 million in 2022, then slipped by 2.27% to $42.9 million in 2023, then declined by 9.04% to $39.0 million in 2024, then slipped by 10.79% to $34.8 million in 2025, then decreased by 0.61% to $34.6 million in 2026.
• Per Business Quant, the three latest GLUE Operating Leases figures stand at $34.6 million (Q1 2026), $34.8 million (Q4 2025), and $35.9 million (Q3 2025).